Scriptaid

Scriptaid is a novel histone deacetylase inhibitor that belongs to an existing class of hydroxamic acid-containing HDAC inhibitors. Scriptaid has a general property of transcriptional facilitation that applies to stably integrated or transiently transfected exogenous constructs, to promoters derived from viruses or an endogenous gene, to multiple reporter genes, and to different cell lines. Scriptaid does not interfere with the ability of a reporter construct to measure the positive activation of a transcription factor in response to a known signal transduction stimulus. In relation to other members of its class, the optimal concentration of scriptaid (6–8 µM) is similar to those reported for CBHA (4 µM) and Suberoylanilide Hydroxamic Acid (2 µM), higher than Trichostatin A (1 µM), and much lower than those reported for EMBA (400 µM) and HMBA (5000 µM).

Synonyms: 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide
Technical Data: Molecular Weight - 326.36; Molecular formula - C18H18N2O4; CAS No - 287383-59-9

Ordering Information: Product Number - EC-000.2460; Price and Availability: Inquire This product is also available to buy in bulk quantities.

References:
1. Su, G.H., Sohn, T.A., Ryu, B., et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60 3137-3142 (2000).
2. Keen, J.C., Yan, L., Mack, K.M., et al. A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor ? (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat 81 177-186 (2003).
3. Lee, E.J., Lee, B.B., Kim, S., et al. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33 767-776 (2008).